People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed. People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed.   Author: Dr Siamak Tonekaboni

People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed. People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed.   Author: Dr Siamak Tonekaboni

Summary: The pediatric and adolescent population is often overlooked in surveys and the burden of disease is essentially unknown particularly in countries with high prevalence rates. It is imperative to determine the brunt of the disease in the pediatric population to fulfill the WHO’s global HCV elimination goals, also diagnose and cure children at an early age before adolescence and behaviors associated with high risk of transmission.

Summary: Most recent and up to date review on HCV diagnosis by Professor Francesco Negro from University Hospital of Geneva, Switzerland. An extensive review on clinical aspects of HCV diagnosis as well as review of most recent technologies and tools available.

Summary: Nominated Best Ensemble for Off West End Awards. A great play about HIV stigma and real-life relationships.

Summary: The World Hepatitis Summit is a public policy three day event bringing together a global audience of civil society groups, WHO and its Member States, patient organisations from the World Hepatitis Alliance’s 249 organisational members, policy-makers, public health scientists and funders.